|
Home : Unsafe Drugs : Avandia : Newsfeeds : Pharma's Most Perilous Pipelines Pharma's Most Perilous Pipelines
Also coming off patent in 2012 is Glaxo's diabetes drug Avandia , which contributed more than $700 million in sales last year. Together, Avandia and Advair represent 24% of Glaxo's total revenues in 2010 and are a major reason Glaxo could be in trouble ...
Avandia Case Evaluation Form
This form is secure and encrypted. More information about secure forms and your privacy here.
|




